C[O:2][C:3]1[C:4](=[O:29])[N:5]([CH3:28])[C:6]([C:23]([N:25]([CH3:27])[CH3:26])=[O:24])=[C:7]2[C:12]=1[C:11](=[O:13])[N:10](CC1C=CC(OC)=CC=1)[CH2:9][CH2:8]2.Br>CC(O)=O>[OH:2][C:3]1[C:4](=[O:29])[N:5]([CH3:28])[C:6]([C:23]([N:25]([CH3:26])[CH3:27])=[O:24])=[C:7]2[C:12]=1[C:11](=[O:13])[NH:10][CH2:9][CH2:8]2In a 50 mL heavy walled glass pressure flask 4-methoxy-6-(4-methoxybenzyl)-N,N,2-trimethyl-3,5-dioxo-2,3,5,6,7,8-hexahydro-2,6-naphthyridine-1-carboxamide (3.9 g) and 15 ml of (commercial) 33% HBr in HOAc were mixed. The flask was sealed, heated to 75° C. and allowed to stir overnight. The solvent was removed in vacuo. The remaining oil was dissolved in CH3CN and purified by reverse phase on a Biotage KPCM 250 compression module containing a 10 cm×60 cm Kiloprep cartridge. The product elutes at 13% CH3CN in water containing 0.1% TFA.
読み込み中…